Search Results
Your search for ,NOt matches 22378 pages
Showing 21901 - 21950Sale of Ponatinib Suspended Due to Risk of Life-Threatening Blood Clots
The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the tyrosine kinase inhibitor ponatinib (Iclusig) to suspend marketing and sales of the drug because of the risk of life-threatening blood clots and severe narrowing of blood vessels. Ariad Pharmaceuticals has agreed to...
Teenagers and Young Adults Diagnosed With Cancer Are at Increased Risk of Suicide
Teenagers and young adults are at increased risk of suicide after being diagnosed with cancer, according to a study published today in Annals of Oncology. A study of nearly 8 million Swedes aged 15 and over found that among the 12,669 young people diagnosed with cancer between the ages of 15 and...
Nivolumab Shows Activity in Ipilimumab-Refractory or -Naive Melanoma in Phase I Trial
In a phase I trial reported in the Journal of Clinical Oncology, Jeffrey S. Weber, MD, of the H. Lee Moffitt Cancer Center and Research Institute, and colleagues assessed the effects of nivolumab—a human immunoglobulin G4-blocking antibody against the T-cell programmed death 1 checkpoint ...
Investigational ALK Inhibitor Shows Promise in Patients With Crizotinib-Refractory, ALK-Positive Non–Small Cell Lung Cancer
Patients with non–small cell lung cancer who have the ALK gene rearrangement usually respond to the drug crizotinib (Xalkori), with a median duration of response of approximately 10 months. In a study reported by Shirish Gadgeel, MD, of Karmanos Cancer Institute in Detroit, and colleagues at...
New ASCO Choosing Wisely® List Details Five Cancer Tests and Treatments Routinely Performed Despite Lack of Evidence
The American Society of Clinical Oncology (ASCO) today announced its second “Top Five” list of opportunities to improve the quality and value of cancer care. Published in the Journal of Clinical Oncology (JCO), ASCO’s second Top Five list was released as part of the Choosing...
No Progression-Free Survival Difference With First-Line Axitinib vs Sorafenib in Metastatic Renal Cell Carcinoma
In a phase III trial reported in The Lancet Oncology, Thomas E. Hutson, DO, PharmD, of Baylor Sammons Cancer Center and colleagues compared the second-generation VEGFR inhibitor axitinib (Inlyta) with sorafenib (Nexavar) as first-line treatment of metastatic renal cell carcinoma. There was no...
Long-Distance Travel for Cancer Care Is Linked to Later-Stage Breast Cancer Diagnosis
The longer a woman with breast cancer has to travel to reach a comprehensive cancer center, the more likely she is to have later-stage disease at diagnosis, and the more likely she is to have a mastectomy, according to study by medical student Krishan Jethwa and colleagues from the University of...
African American Women Are Less Likely to Benefit From HPV Vaccines for Cervical Cancer Prevention
Vaccines currently available to prevent the two most common strains of human papillomavirus (HPV), HPV 16 and 18, responsible for about 70% of cervical cancers, may not be protective in African American women, according to a study by Cathrine Hoyo, PhD, MPH, Associate Professor in the Obstetrics...
Shortened Telomeres in Blood Leukocytes May Be Associated With Increased Risk of Aggressive Prostate Cancer
Men with short-ended chromosomes in the immune cells in their blood were at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes in blood immune cells, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer...
New Biomarker May Differentiate Progressive From Nonprogressive Ductal Carcinoma in Situ
Measuring the presence and amount of the protein Vav2 may help identify breast precancers that will progress to invasive cancers, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held October 27 to 30 in National Harbor,...
Multiple Myeloma Defined by Light Chain Amyloidosis With Plasma Cell or CRAB Criteria
In a study reported in Journal of Clinical Oncology, Taxiarchis V. Kourelis, MD, and colleagues from the Mayo Clinic attempted to define a threshold of bone marrow plasma cell number that could serve to define light chain amyloidosis as light chain amyloidosis with multiple myeloma. They found that ...
Dose-Limiting Late Toxicity Observed After Hypofractionated Dose-Escalated Radiotherapy in NSCLC
In a phase I study reported in Journal of Clinical Oncology, Donald M. Cannon, MD, of University of Wisconsin School of Medicine and Public Health and Mountain States Tumor Institute, and colleagues attempted to identify the maximum tolerated dose of dose-escalated hypofractionated radiation...
Urologist Ownership of Intensity-Modulated Radiation Therapy Services Significantly Increases Use of Treatment for Prostate Cancer
In a study reported in The New England Journal of Medicine, Jean M. Mitchell, PhD, of Georgetown University, examined patterns of use of intensity-modulated radiation therapy to treat prostate cancer among urologists in private practice who have integrated intensity-modulated radiation therapy into ...
FDA Approves First Extended-Release, Single-Entity Hydrocodone Product
The U.S. Food and Drug Administration (FDA) today approved hydrocodone bitartrate extended-release capsules (Zohydro ER) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate. The drug, a Schedule ...
The Impact of the Affordable Care Act on Oncology Care
According to the Congressional Budget Office, over the next 10 years, the Patient Protection and Affordable Care Act will result in approximately 25 million newly insured individuals and 12 million more Medicaid beneficiaries through the the Medicaid expansion provision. While the law provides...
Complete Sequencing of All Known Breast Cancer Genes Explains Occurrence of the Cancer in Women With Normal BRCA Genes
Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2, and the vast majority of those patients were told that their gene sequences were normal. With the development of modern genomics...
Novel Gene-Diet Interaction May Explain Association Between Red and Processed Meat Consumption and Colorectal Cancer Risk
A newly discovered potential gene-diet interaction for colorectal cancer may shed light on the statistically significant increased risk of colorectal cancer that is associated with consumption of red and processed meat, according to a study reported yesterday at the American Society of Human...
Study Clarifies Value—and Limitations—of Patient Assistance Programs for Women With Breast Cancer
Patient assistance programs can help patients with breast cancer meet a variety of needs that might otherwise interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of...
Bone Marrow Transplant Linked to Negative Sexual Side Effects in Both Men and Women
New research ties preparative procedures and complications associated with blood or bone marrow transplant with diminished sexual health in both men and women who have undergone the procedure. Study data, published today in Blood, confirm chronic graft-vs-host disease as a potential source of...
Combining Metformin With Chemotherapy and Radiation May Improve Outcomes in Lung Cancer Patients
Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggested new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania. The findings will be presented by...
Perioperative FOLFOX4 Does Not Improve Overall Survival vs Surgery Alone in Patients With Resectable Liver Metastases From Colorectal Cancer
Previously reported results of the phase III EORTC intergroup 40983 trial showed that perioperative chemotherapy with FOLFOX4 (leucovorin, fluorouracil [5-FU], and oxaliplatin) increased progression-free survival compared with surgery alone in patients with initially resectable liver metastases...
New Biomarker May Help Guide Treatment of Melanoma Patients
A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held...
New Molecular Diagnostics Platform Enables Rapid Detection of BRAF V600 Mutations
A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented at the AACR-NCI-EORTC International...
Phase II Study Supports Axitinib Dose Titration in Select Treatment-Naive Metastatic Renal Cell Carcinoma Patients
Axitinib plasma exposure may correlate with efficacy in metastatic renal cell carcinoma, according to population pharmacokinetic data. In a phase II study reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic, and colleagues evaluated the effects of axitinib dose titration in...
Association Between Prevalence of Symptoms and Impaired Health-Related Quality of Life in Adult Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, I-Chan Huang, PhD, of University of Florida at Gainesville, and colleagues investigated the association between prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer enrolled in the St. Jude...
Sequential Addition of Gemtuzumab Ozogamicin to Standard Chemotherapy of No Benefit in Older Patients With Newly Diagnosed AML
In a phase III trial (EORTC [European Organisation for Research and Treatment of Cancer]/GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] consortium AML-17 trial) reported in the Journal of Clinical Oncology, Sergio Amadori, MD, of Tor Vergata University Hospital in Rome, and...
Imatinib Rechallenge Slows Disease Progression in Patients With Metastatic or Unresectable GIST After Imatinib and Sunitinib
In the RIGHT trial, reported in The Lancet Oncology, Yoon-Koo Kang, MD, of University of Ulsan College of Medicine in Seoul, and colleagues assessed the effects of imatinib (Gleevec) rechallenge in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) after objective...
Novel Drug Combinations Targeting Pathways Triggered by KRAS May Benefit Patients With Pancreatic Cancer
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented at the AACR-NCI-EORTC...
New Nanopharmaceutical May Be Able to Overcome Resistance to Antiangiogenic Treatment
The nanopharmaceutical CRLX101, a novel inhibitor of topoisomerase-1 and hypoxia-inducible factor (HIF)-1 alpha, may be capable of overcoming resistance of tumors to antiangiogenic agents, according to preclinical and early clinical studies that have evaluated CRLX101 in combination with...
Risk of Congestive Heart Failure Increased With Trastuzumab Use in Older Breast Cancer Patients
Risk and risk factors for congestive heart failure in older breast cancer patients receiving trastuzumab have not been clearly defined. In a study reported in the Journal of Clinical Oncology, Mariana Chavez-MacGregor, MD, of The University of Texas MD Anderson Cancer Center, and colleagues...
FDA Investigating Ponatinib After Increased Reports of Serious Blood Clots in Arteries and Veins
The U.S. Food and Drug Administration (FDA) is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels of patients taking the antileukemia drug ponatinib (Iclusig). Ponatinib is indicated for the treatment of patients with...
Improved Progression-Free but Not Overall Survival With Addition of Maintenance Erlotinib to Bevacizumab After Chemotherapy Plus Bevacizumab in NSCLC
In the phase IIIB ATLAS trial reported in the Journal of Clinical Oncology, Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, and colleagues assessed the addition of maintenance erlotinib (Tarceva) to bevacizumab (Avastin) following chemotherapy plus bevacizumab in first-line treatment of ...
Increased Radiation Dose With Hypofractionated vs Conventional Radiation Therapy Does Not Improve Biochemical/Clinical Failure Rate in Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Alan Pollack, MD, PhD, of University of Miami Miller School of Medicine, and colleagues compared escalated radiation dose using hypofractionated vs conventional fractionation intensity-modulated radiation therapy in men with favorable-...
STAG2 Mutation Found Linked to Low-Risk Bladder Cancer
An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. The findings, published in Nature Genetics, identified STAG2 as one of the most commonly mutated genes in bladder cancer,...
Inflammatory vs Noninflammatory Breast Cancers of Same Estrogen Receptor Status Have Varying Risk Factor Associations
In a study reported in the Journal of the National Cancer Institute, Catherine Schairer, PhD, from the National Cancer Institute, and colleagues investigated risk factors associated with inflammatory breast cancer. Among their findings was that high body mass index (BMI) increased inflammatory ...
Increased Risk of Long-Term Cardiovascular Mortality and All-Cause Mortality in Patients With Differentiated Thyroid Carcinoma
In a study reported in the Journal of Clinical Oncology, Esther N. Klein Hesselink, of University Medical Center Groningen in the Netherlands, and colleagues evaluated long-term cardiovascular mortality in patients with differentiated thyroid cancer. They found that risk of cardiovascular and...
Simple Blood Test May Diagnose Lung and Other Cancers
A simple blood test that measures serum free fatty acids and their metabolites may detect early-stage lung cancer and its recurrence, according to a study from The Cleveland Clinic presented at the ANESTHESIOLOGY™ 2013 Annual Meeting in San Francisco (Abstract A4267). The study was presented ...
Optical Metabolic Imaging Can Identify Breast Cancer Subtypes and Early Treatment Response
An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as 2 days after therapy administration, according to a study published in Cancer Research. “The process of...
Breast Cancer Risk Differs by Race, BMI, Breast Density Among Hormone Replacement Therapy Users
In a study reported in the Journal of the National Cancer Institute, Ningqi Hou, PhD, of University of Chicago, and colleagues analyzed the potential contribution of patient characteristics to risk of breast cancer associated with hormone replacement therapy. The study found that risk of...
No Benefit of Dose-Dense vs Standard Temozolomide in Newly Diagnosed Glioblastoma, MGMT Methylation Associated With Better Survival
Dose-dense temozolomide results in depletion of O6-methylguanine-DNA methyltransferase (MGMT)—a potential determinant of treatment response—in blood mononuclear cells and possibly in tumors. In a phase III trial (Radiation Therapy Oncology Group [RTOG] 0525) reported in the Journal ...
Standard and Reduced High-Dose Volume Radiation Therapy for Muscle-Invasive Bladder Cancer Have Comparable Tumor Control
Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide comparable tumor control and decreased late toxicity when compared to surgery, according to a study published in the October issue of the International Journal of Radiation Oncology...
Similar High Complete Response Rate With Neoadjuvant Trastuzumab, Lapatinib, and Combined Therapy in HER2-Positive Breast Cancer
In a phase III trial (NSABP B-41) performed to assess the potential benefit of neoadjuvant dual HER2 blockade in HER2-positive breast cancer, André Robidoux, MD, of Centre Hospitalier de l’Université de Montréal and colleagues in the National Surgical Adjuvant Breast and...
No Additional Benefit of Venlafaxine or Soy Protein vs Placebo on Hot Flashes in Men With Prostate Cancer
Hot flashes occur in approximately 80% of androgen-deprived men. In a randomized study reported in the Journal of Clinical Oncology by Mara Z. Vitolins, DrPH, MPH, RD, of Wake Forest School of Medicine, and colleagues, neither venlafaxine nor soy protein—both of which have been used to...
Promising Outcomes With R-MPV Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Patrick G. Morris, MD, of Memorial Sloan-Kettering Cancer Center, and colleagues assessed the efficacy of rituximab (Rituxan), methotrexate, procarbazine (Matulane), and vincristine (R-MPV) followed by consolidation reduced-dose ...
Women With Lower Pretreatment Estrogen Levels at Greater Risk of Breast Cancer During Estrogen-Plus-Progestin Therapy
In a study reported in the Journal of the National Cancer Institute, Ghada N. Farhat, PhD, of University of Balamand in Beirut, and colleagues found that women with lower pretreatment endogenous estrogen levels are at greatest risk of breast cancer during estrogen-plus-progestin therapy. Study...
Outcome Improved in MET-Positive and Worsened in MET-Negative NSCLC With Addition of Onartuzumab to Erlotinib in Phase II Trial
In patients with non–small cell lung cancer (NSCLC), increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to EGFR-targeted treatment. In a phase II study reported in the Journal of Clinical Oncology, David R. Spigel, MD, of Sarah...
PAM50 Risk of Recurrence Score Provides Strongest Prognostic Information for Risk Beyond 5 Years in Estrogen Receptor–Positive Breast Cancer
Adjuvant endocrine therapy beyond 5 years reduces recurrence in patients with estrogen receptor–positive breast cancer. Recent studies from the transATAC cohort have shown that immunohistochemical markers (IHC4), Oncotype DX recurrence score, and PAM50 risk of recurrence score are associated...
Gemcitabine Improves Overall Survival Following Surgery for Pancreatic Cancer
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in published in the October 9 issue of...
Substantial Proportion of Older Patients Receiving First-Line Chemotherapy Experience Functional Decline
In a study reported in Journal of Clinical Oncology, Stéphanie Hoppe, PhD, of Institut Bergonié in Bordeaux, France, and colleagues assessed functional status in older patients with cancer receiving first-line chemotherapy using the Activities of Daily Living (ADL) scale. Clinically...
Researchers Identify Potential New Drug for Inherited Cancer
Scientists from The Scripps Research Institute have identified a new drug candidate for an inherited form of cancer with no known cure. The new study showed the drug candidate—known as FRAX97—slowed the proliferation and progression of tumor cells in animal models of neurofibromatosis...
